Owing to the advent of the chimeric antigen receptor (CAR), cell-based immunotherapy has provided a unique avenue to treating oncological malignancies that are currently limited by traditional treatments such as chemotherapy and radiation. More recently, the use of engineered natural killer (NK) cells expressing CARs (CAR-NK) have been shown to possess an improved safety profile compared to CAR-T cells, making CAR-NKs a desirable treatment option for many cancers. However, primary sources ...